Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
One dead, six wounded in various crime-related shootings in Israel over the weekend- Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- Make your choice for a definitive Christmas getaway destination!
- People are getting their news from AI – and it’s altering their views
- Solid Propensities: Little Changes for a Superior Life
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- How food assistance programs can feed families and nourish their dignity
- CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
